Event Details

Overview

In a decentralised clinical trial, patients' assessments are (partly) transferred from the clinical trial site to the patients' home and might occur without any face to face interactions between patient and study personnel. In particular during the Covid-19 pandemic, decentralising clinical trials attracted considerable attention as one way to continue conducting trials during lockdowns and curfews. In this online event, experts in the field discuss the opportunities and challenges of decentralised clinical trials for the development of drugs and the promise they hold for modernising the way trials are conducted.


Who is this event intended for? Statisticians or those in other quantitative disciplines working on - or interested in - learning about decentralised clinical trials.

What is the benefit of attending? Attendees will hear about the application and opportunities of decentralised clinical trials in drug development from experts in the field, both statistical and operational.


Time: 13:30-16:30 BST (both days) | 14:30-17:30 CEST | 08:30-11:30 EDT

Speakers: David Wright (AstraZeneca), Magnus Jörnten-Karlsson (AstraZeneca), Magalie Hilton (Roche), Yashoda Sharma (DiMe), Khadija Rantell (MHRA), Rima Izem (Novartis) and Rachel Williams (GSK).

Tickets

PSI Member
Member Price £20
PSI Non-Member
Standard Price £130

Speakers

  • David Wright (Head of Statistical Innovation at AstraZeneca)

    David Wright

    Head of Statistical Innovation at AstraZeneca

  • Magnus Jörnten‐Karlsson (Executive Product Director of AstraZeneca)

    Magnus Jörnten‐Karlsson

    Executive Product Director of AstraZeneca

  • Magalie Hilton (Senior Principal Statistical Scientist at Roche)

    Magalie Hilton

    Senior Principal Statistical Scientist at Roche

  • Yashoda Sharma (Program Director of Digital Medicine Society (DiMe))

    Yashoda Sharma

    Program Director of Digital Medicine Society (DiMe)

  • Khadija Rantell (Senior Statistical Assessor at MHRA)

    Khadija Rantell

    Senior Statistical Assessor at MHRA

  • Rima Izem (Associate Director of Novartis Pharma AG)

    Rima Izem

    Associate Director of Novartis Pharma AG

  • Rachel Williams (Head of Opportunistic, ID, and Respiratory Epidemiology at GSK)

    Rachel Williams

    Head of Opportunistic, ID, and Respiratory Epidemiology at GSK

Community

Connect with 12 people attending this event